Abbott Surges with Diagnostics and Diabetes | Business and Finance News

Abbott’s latest earnings crush expectations, fueled by a soaring cancer diagnostics division that’s offsetting the decline in COVID-19 testing. Key products like Cologuard and Oncotype DX are driving growth, while medical devices and diabetes care (including FreeStyle Libre) surge with double-digit gains. Despite industry headwinds from fewer elective surgeries and rising uninsured rates, Abbott shines with a 9% jump in medical devices and a 11% boost in diabetes sales. Adjusted EPS hits $1.31—beating estimates—and revenue climbs to $12.59B. They’re also raising their 2026 profit forecast, signaling confidence in their resilient, diversified future. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7e857f32650cee1f